Australia markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.83+0.19 (+1.14%)
At close: 04:00PM EST
16.99 +0.16 (+0.95%)
Pre-market: 06:36AM EST
Full screen
Loading interactive chart…
  • PR Newswire

    World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescen

  • Zacks

    Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

    Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

  • Motley Fool

    Is Novavax Stock a Buy Now?

    Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Importantly, Gavi has paid Novavax $700 million in the last two years, and its $350 million payment in 2021 accounted for a large fraction of the biotech's $1.1 billion in total revenue for the year.